Oliver Cox - Publications

Beyond Cost: Faricimab as a Driver of Service Efficiency and Quality in Neovascular Age-Related Macular Degeneration Care.

Journal: Ophthalmology and therapy

Published: October 23, 2025

The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America.

Journal: Ophthalmology and therapy

Published: March 24, 2025

Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review.

Journal: Ophthalmology and therapy

Published: June 18, 2024

Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema.

Journal: Ophthalmology and therapy

Published: May 24, 2024

Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: May 23, 2024

An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.

Journal: Eye (London, England)

Published: July 13, 2023

Health technology assessment of new retinal treatments; the need to capture healthcare capacity issues.

Journal: Eye (London, England)

Published: April 29, 2022

Health technology assessments and real-world evidence: tell us what you want, what you really, really want.

Journal: Journal of comparative effectiveness research

Published: February 25, 2022

The (Harsh) Reality of Real-World Data External Comparators for Health Technology Assessment.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 10, 2021